CTLA-4 inhibitor

Research use only, not for human use.

CTLA-4 inhibitor is a potent CTLA-4 inhibitor.

MDK24720 is a CTLA-4 inhibitor. MDK24720 has CAS#635324-72-0, in which the last 5 digital was used in the code name. CTLA4 or CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), also known as CD152 (cluster of differentiation 152), is a protein receptor that, functioning as an immune checkpoint, downregulates immune responses. CTLA4 is constitutively expressed in Tregs but only upregulated in conventional T cells after activation. It acts as an "off" switch when bound to CD80 or CD86 on the surface of antigen-presenting cells. Polymorphisms of the CTLA-4 gene are associated with autoimmune diseases such as autoimmune thyroid disease and multiple sclerosis, though this association is often weak. In Systemic Lupus Erythematosus (SLE), the splice variant sCTLA-4 is found to be aberrantly produced and found in the serum of patients with active SLE.

Bivalent CTLA4 homodimers bridge bivalent B7.1 homodimers to form an unusually stable signaling complex. Blocking B7/CD28 interactions with monoclonal antibodies or soluble receptors results in immunosuppression and enhanced allograft survival, while B7/CTLA-4 blockade results in enhanced antitumor immune responses. The interaction of co-stimulatory molecules on T cells with B7 molecules on antigen presenting cells plays an important role in the activation of naive T cells. Consequently, agents that disrupt these interactions should have applications in treatment of transplant rejection as well as autoimmune diseases.

——

MDK24720 | MDK-24720 | CTLA-4 inhibitor

Angiogenesis

IGF-1R

CTLA-4

——

——

635324-72-0

427.11

C21H13F4N5O

>98% (HPLC)

In Vitro:?DMSO : 62.5 mg/mL (146.25 mM)

c12c(nc3c(c1[nH]n(c2=O)c1ccc(cc1)F)cnn3C)c1cc(ccc1)C(F)(F)F

2-(4-Fluoro-phenyl)-6-methyl-4-(3-trifluoromethyl-phenyl)-1,6-dihydro-2H-1,2,5,6,7-pentaaza-as-indacen-3-one

(-20℃)

With Ice Pack

≥ 2 years